Mozz's scientific paragraph of the year..., page-14

and we also have to understand, rightly or wrongly, PAR would be filtered out of many investment managers watchlist based on its pre revenue biotech status, it would sit outside of their investment analyst/committee field of expertise, looming capital requirements, biotechnology sector having burnt them in the past etc etc. if I’m a fund manager I’ve spent 0 mins in the last 18 months thinking outside the box. I’ve been scrambling hard to keep up with my peers. I want to keep my job, maintain my FUM and I’ve got big bills to pay… the holiday house, private school fees, mortgage the ex wife and so on aren’t going to pay for themselves. So despite the compelling nature of the investment…. Retail investors do the work for now. It’s could change rapidly…. As we all point out. Then watch them scrambling for content and knowledge of this molecule and how it’s structured up to command status in the asx 50 one day.